We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » STUDY: GENERIC DRUG COMBINATION PREVENTS BIRD FLU

STUDY: GENERIC DRUG COMBINATION PREVENTS BIRD FLU

May 19, 2006

The generic drugs amantadine and rimantadine could be effective against the avian flu, according to a study to be published in the next issue of the Journal of Infectious Diseases.

Most strains of the lethal avian influenza virus H5N1 -- which has killed more than half of the 207 people it has infected -- could be treated with these older antivirals, the study says.

"Amantadine appears to retain the potential to be useful in an H5N1 pandemic in the absence of a vaccine, as a prophylactic agent and as a component of combination antiviral therapy," study authors say.

Both drugs are available in generic formulations from multiple sources, including Sandoz for amantadine and Impax for rimantadine, according to the FDA.

Researchers analyzed 638 H5N1 viruses of human and avian origin from Hong Kong and eight Asian nations. More than 90 percent of the virus strains from Vietnam and Cambodia had mutations that made them resistant to amantadine and rimantadine, but only 6.3 percent of the strains from Indonesia and 8.9 percent from China had these mutations.

The study can be found at http://www.journals.uchicago.edu/ucp/WebIntegrationServlet?call=ContentWeblet&url=http://www.journals.uchicago.edu/JID/journal/issues/v193n12/36344/36344.web.pdf¤t_page=content (http://www.journals.uchicago.edu/ucp/WebIntegrationServlet?call=ContentWeblet&url=http://www.journals.uchicago.edu/JID/journal/issues/v193n12/36344/36344.web.pdf¤t_page=content).

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing